Michelle Rheault, MD, joined the Division of Pediatric Nephrology as an Assistant Professor in 2008 and is currently Division Director and the medical director of dialysis at University of Minnesota Masonic Children's Hospital. Dr. Rheault is a member of the American Society of Nephrology and serves as co-chair of the program committee of the American Society of Pediatric Nephrology. Dr. Rheault has been involved in research on Alport Syndrome since 2002 and helped characterize the first mouse model of X-linked Alport Syndrome. She also has a special interest in treatment and outcomes for women with X-linked Alport syndrome. Dr. Rheault's other clinical research interests include nephrotic syndrome, dialysis, and kidney transplantation outcomes and complications. Dr. Rheaultis currently co-director of the Alport Syndrome Treatment and Outcomes Registry (ASTOR) and an investigator in clinical trials of new therapies for patients with Alport syndrome. Dr. Rheault has written a number of book chapters, reviews, and original science articles about Alport syndrome. In addition, she is on the steering committee for the Midwest Pediatric Nephrology Consortium and a member of the American Board of Pediatrics Subboard of Pediatric Nephrology.